Identification of the efficacy and safety of apomorphine in the treatment of Parkinson’s disease via meta-analysis [PDF]
BMC NeurologyBackground The majority of Parkinson’s disease (PD) patients experience motor fluctuations and dyskinesias as the disease progresses. Apomorphine has been used as an acute treatment for off episodes in PD in recent years.
Haidong Li +3 more
doaj +2 more sources
Licensed Subcutaneous Infusion Therapies in Advanced Parkinson’s Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis [PDF]
Neurology and TherapyIntroduction Parkinson’s disease is the second most common neurodegenerative disorder. In advanced Parkinson’s disease, subcutaneous (SC) infusion therapies represent minimally invasive and reversible treatment options.
Marc Vérin +9 more
doaj +2 more sources
Ophthalmic ropinirole is an equally effective emetic agent in healthy dogs compared to intravenous apomorphine [PDF]
Frontiers in Veterinary ScienceIntroductionEmesis is commonly induced in the veterinary setting due to toxin or foreign material ingestion. The dopamine agonist apomorphine is commonly used for this indication.
Jack A. Lee +3 more
doaj +2 more sources
Clinical and Translational Science, 2021 Apomorphine is an on‐demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD). A joint parent‐metabolite population pharmacokinetic (PK) model characterized apomorphine and apomorphine‐sulfate following administration of apomorphine ...
Felix Agbo +6 more
doaj +1 more source
A double-blind study of the efficacy of apomorphine and its assessment in "off-periods in Parkinson's disease [PDF]
, 1993 Five patients with idiopathic Parkinson's disease with severe response fluctuations were selected for a randomized double-blind placebo-controlled study, concerning the clinical effects of subcutaneous apomorphine and its assessment in `off¿-periods. The
Essink, A.W.G. +4 more
core +6 more sources
Clinical Parkinsonism & Related Disorders, 2023 Introduction: Pretreatment with the antiemetic trimethobenzamide has been recommended practice in the United States (US) to address the risk of nausea and vomiting during initiation of apomorphine treatment.
Stuart H. Isaacson +3 more
doaj +1 more source
Subcutaneous apomorphine in advanced Parkinson’s disease and its use in Indian population
Annals of Movement Disorders, 2020 Although subcutaneously administered apomorphine is widely used as an effective adjunct therapy for Parkinson’s disease (PD), it was approved for use in India only in 2019. This review summarizes the history, pharmacology, clinical spectrum, indications,
Vinod Metta +7 more
doaj +1 more source
Ankk1 Loss of Function Disrupts Dopaminergic Pathways in Zebrafish
Frontiers in Neuroscience, 2022 Ankyrin repeat and kinase domain containing 1 (ANKK1) is a member of the receptor-interacting protein serine/threonine kinase family, known to be involved in cell proliferation, differentiation and activation of transcription factors.
Adele Leggieri +9 more
doaj +1 more source
Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment [PDF]
, 1997 Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a significant problem in the optimal management of idiopathic Parkinson's disease.
Abbott, R.J. +6 more
core +2 more sources
Motor Evoked Potentials Improve Targeting in Deep Brain Stimulation Surgery
Neuromodulation: Technology at the Neural Interface, EarlyView., 2021 Abstract Objectives One of the main challenges posed by the surgical deep brain stimulation (DBS) procedure is the successful targeting of the structures of interest and avoidance of side effects, especially in asleep surgery. Here, intraoperative motor evoked potentials (MEPs) might serve as tool to identify the pyramidal tract.
Petyo Nikolov +7 more
wiley +1 more source